search
Back to results

Light Needle for Opioid Use Disorder (OUD)

Primary Purpose

Opioid Use Disorder

Status
Recruiting
Phase
Not Applicable
Locations
Taiwan
Study Type
Interventional
Intervention
Light needle therapy
Sham light needle therapy
Sponsored by
Chang Gung Memorial Hospital
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Opioid Use Disorder focused on measuring Light needle, Opioid use disorder, Heroin addiction, Methadone maintenance treatment, Traditional Chinese medicine

Eligibility Criteria

20 Years - 70 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • A diagnosis of OUD is confirmed using the diagnostic criteria of the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition. Subjects aged 20-70 years with OUD who have received methadone maintenance treatment for at least 1 month and provided informed consent are being recruited. Psychiatrists assess each prospective participant's eligibility to be enrolled in the study.

Exclusion Criteria:

  • Subjects with a critical illness
  • those who have taken Chinese herbs or received acupuncture treatment during the previous 30 days
  • those who are unsuitable for recruitment in the opinion of the attending physician
  • those who are unwilling to provide informed consent are excluded.

Sites / Locations

  • Kaohsiung Chang Gung Memorial HospitalRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Sham Comparator

Arm Label

light needle therapy

sham light needle therapy

Arm Description

The study participants will receive 12 sessions of light needle therapy within 4 weeks using a gallium aluminum arsenide Physiolaser olympic (maximal power, 60mW; wavelength, 655 nm; area of probe, 0.008 cm2; power density, 7.5 W/cm2; pulsed-wave; RJ-Laser, Reimers & Janssen GmbH, Waldkirch, Germany). Those in the experimental group received a total 135 J of energy delivered from 6 light needles being placed between LU7 and LU9. The light needle therapy was applied to each point for 15 min.

The study participants will receive 12 sessions of sham light needle therapy, without any laser output (no stimulation), within 4 weeks using a gallium aluminum arsenide Physiolaser olympic. Those in the control group received 0 J of energy delivered from 6 light needles being placed between LU7 and LU9 for 15 min.

Outcomes

Primary Outcome Measures

urinary morphine levels
morphine levels in urine
times or days of heroin use during the previous week
self-reported times or days of heroin use during the previous week

Secondary Outcome Measures

self-reported visual analogue scale (VAS) scores for heroin craving/refusal to use heroin (0-10 points) in the previous week
A VAS score of 0 for heroin craving indicates no heroin craving and a score of 10 indicates the strongest possible heroin craving. A VAS score of 0 for refusal to use heroin indicates no refusal and a score of 10 indicates total refusal.
self-reported quality of life using the Short Form-12v2®
The PRO CoRE will be used to score the SF-12v2 Health Survey.
pulse diagnosis and heart rate variability
pulse diagnosis and heart rate variability will be recorded.

Full Information

First Posted
April 18, 2022
Last Updated
May 2, 2023
Sponsor
Chang Gung Memorial Hospital
Collaborators
Kaohsiung Medical University
search

1. Study Identification

Unique Protocol Identification Number
NCT05341219
Brief Title
Light Needle for Opioid Use Disorder
Acronym
OUD
Official Title
Effect of Light Needle in the Treatment of Opioid Use Disorder: A Randomized Controlled Trial
Study Type
Interventional

2. Study Status

Record Verification Date
May 2023
Overall Recruitment Status
Recruiting
Study Start Date
March 18, 2022 (Actual)
Primary Completion Date
February 14, 2024 (Anticipated)
Study Completion Date
February 14, 2024 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Chang Gung Memorial Hospital
Collaborators
Kaohsiung Medical University

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
This randomized-controlled study investigates the effect of adjuvant light needle in the treatment of heroin addicts. One hundred heroin addicts older than 20 years old enrolled from the Addiction Treatment Center at Kaohsiung Chang Gung Memorial Hospital and Department of Psychiatry at Kaohsiung Medical University Hospital are randomly allocated to experimental or control group. Subjects in experimental group are treated with light needle on the wrist pulse (Cunkou) 12 times within 4 weeks. Subjects in the control group received a sham light needle treatment, without any laser output. Outcome measurements include check of urine morphine, report of the subjects' times or days of heroin use, self-filling Visual Analogue Scales of heroin craving / refusal of heroin use (0-10 points) during last week, report of the subjects' quality of life using Short Form-12v2, and record of the subject's pulse diagnosis and heart rate variability before and after treatment.
Detailed Description
Background: Heroin addiction remains a significant public health problem worldwide, and relapse to heroin use following cessation of agonist maintenance treatment is common. The problems associated with use of opioid agonists mean that non-opioid therapies need to be developed to ameliorate acute and protracted opioid withdrawal syndromes. Objective: To investigate the effect of adjuvant light needle therapy in patients with opioid use disorder on methadone maintenance treatment. Methods: One hundred participants with opioid use disorder on methadone maintenance treatment will be enrolled from the addiction treatment center at Kaohsiung Chang Gung Memorial Hospital and Department of Psychiatry at Kaohsiung Medical University Hospital, and randomly allocated to the experimental or control group. The experimental group is receiving 12 sessions of light needle therapy within 4 weeks. The control group is receiving sham light needle treatment, without any laser output. Urinary morphine levels are being checked before and after treatment. Subjects are requested to self-report their number of episodes or days of heroin use and 0-10-point visual analogue scale scores for heroin craving/refusal to use heroin during the previous week before and after treatment. Quality of life will be reported using the Short Form-12v2 before and after 4 weeks of treatment. Pulse diagnosis will be recorded and heart rate variability calculated before and after treatment. The baseline patient characteristics will be compared between the experimental and control groups using the independent t-test and chi-square test. Data are compared between the two groups using repeated-measures analysis of variance, generalized estimating equations, and the paired t-test.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Opioid Use Disorder
Keywords
Light needle, Opioid use disorder, Heroin addiction, Methadone maintenance treatment, Traditional Chinese medicine

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Model Description
Subjects recruited from the two institutions are being randomly allocated to the experimental group (light needle plus methadone maintenance treatment, n = 50, expected), or the control group (light needle without laser output plus methadone maintenance treatment, n = 50, expected). The study participants will receive 12 sessions of light needle therapy within 4 weeks.
Masking
ParticipantOutcomes Assessor
Masking Description
Allocation concealment was implemented through the use of numbered containers. The allocation sequence was concealed from the researcher enrolling and assessing participants in sequentially numbered, opaque, sealed, and stapled envelopes. The trial participants, outcome assessors, and data analysts will be blinded after assignment to interventions using label A and B for the two groups.
Allocation
Randomized
Enrollment
100 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
light needle therapy
Arm Type
Experimental
Arm Description
The study participants will receive 12 sessions of light needle therapy within 4 weeks using a gallium aluminum arsenide Physiolaser olympic (maximal power, 60mW; wavelength, 655 nm; area of probe, 0.008 cm2; power density, 7.5 W/cm2; pulsed-wave; RJ-Laser, Reimers & Janssen GmbH, Waldkirch, Germany). Those in the experimental group received a total 135 J of energy delivered from 6 light needles being placed between LU7 and LU9. The light needle therapy was applied to each point for 15 min.
Arm Title
sham light needle therapy
Arm Type
Sham Comparator
Arm Description
The study participants will receive 12 sessions of sham light needle therapy, without any laser output (no stimulation), within 4 weeks using a gallium aluminum arsenide Physiolaser olympic. Those in the control group received 0 J of energy delivered from 6 light needles being placed between LU7 and LU9 for 15 min.
Intervention Type
Procedure
Intervention Name(s)
Light needle therapy
Intervention Description
The study participants will receive 12 sessions of light needle therapy within 4 weeks using a gallium aluminum arsenide Physiolaser olympic (maximal power, 60mW; wavelength, 655 nm; area of probe, 0.008 cm2; power density, 7.5 W/cm2; pulsed-wave; RJ-Laser, Reimers & Janssen GmbH, Waldkirch, Germany). Those in the experimental group received a total 135 J of energy delivered from 6 light needles being placed between LU7 and LU9. The light needle therapy was applied to each point for 15 min.
Intervention Type
Procedure
Intervention Name(s)
Sham light needle therapy
Intervention Description
The study participants will receive 12 sessions of sham light needle therapy, without any laser output (no stimulation), within 4 weeks using a gallium aluminum arsenide Physiolaser olympic. Those in the control group received 0 J of energy delivered from 6 light needles being placed between LU7 and LU9 for 15 min.
Primary Outcome Measure Information:
Title
urinary morphine levels
Description
morphine levels in urine
Time Frame
4 weeks
Title
times or days of heroin use during the previous week
Description
self-reported times or days of heroin use during the previous week
Time Frame
4 weeks
Secondary Outcome Measure Information:
Title
self-reported visual analogue scale (VAS) scores for heroin craving/refusal to use heroin (0-10 points) in the previous week
Description
A VAS score of 0 for heroin craving indicates no heroin craving and a score of 10 indicates the strongest possible heroin craving. A VAS score of 0 for refusal to use heroin indicates no refusal and a score of 10 indicates total refusal.
Time Frame
4 weeks
Title
self-reported quality of life using the Short Form-12v2®
Description
The PRO CoRE will be used to score the SF-12v2 Health Survey.
Time Frame
4 weeks
Title
pulse diagnosis and heart rate variability
Description
pulse diagnosis and heart rate variability will be recorded.
Time Frame
4 weeks

10. Eligibility

Sex
All
Minimum Age & Unit of Time
20 Years
Maximum Age & Unit of Time
70 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: A diagnosis of OUD is confirmed using the diagnostic criteria of the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition. Subjects aged 20-70 years with OUD who have received methadone maintenance treatment for at least 1 month and provided informed consent are being recruited. Psychiatrists assess each prospective participant's eligibility to be enrolled in the study. Exclusion Criteria: Subjects with a critical illness those who have taken Chinese herbs or received acupuncture treatment during the previous 30 days those who are unsuitable for recruitment in the opinion of the attending physician those who are unwilling to provide informed consent are excluded.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Cheng-Yi Chang
Phone
+886-3-3196200
Ext
3713
Email
ccyi@cgmh.org.tw
First Name & Middle Initial & Last Name or Official Title & Degree
Mer-Lin Chi
Phone
+886-3-3196200
Ext
3702
Email
merlinchi@cgmh.org.tw
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Wen-Long Hu, MD, MS
Organizational Affiliation
Chief, Division of Acupuncture, Kaohsiung Chang Gung Memorial Hospital
Official's Role
Principal Investigator
Facility Information:
Facility Name
Kaohsiung Chang Gung Memorial Hospital
City
Kaohsiung
ZIP/Postal Code
833
Country
Taiwan
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Wen-Long Hu, MD, MS
Phone
+886-7-7317123
Ext
2335
Email
oolonghu@gmail.com

12. IPD Sharing Statement

Learn more about this trial

Light Needle for Opioid Use Disorder

We'll reach out to this number within 24 hrs